舒洛地特对糖尿病肾病患者多种尿蛋白的改善效果及安全性研究  

Improvement effect and safety of sulodexide on various urine proteins in patients with diabetic nephropathy

作　　者：张梦 张伟[2] 王爱凤 鲁平 范晓光 ZHANG Meng;ZHANG Wei;WANG Aifeng;LU Ping;FAN Xiaoguang(Pharmaceutical Department,Fuwai Central China Cardiovascular Hospital/Heart Center of Henan Provincial People's Hospital,Zhengzhou,Henan 450003,China;Pharmaceutical Department,Henan Provincial People's Hospital,Zhengzhou,Henan 450003,China;Department of Endocrinology,Fuwai Central China Cardiovascular Hospital/Heart Center of Henan Provincial People's Hospital,Zhengzhou,Henan 450003,China;Department of nephrology,Fuwai Central China Cardiovascular Hospital/Heart Center of Henan Provincial People's Hospital,Zhengzhou,Henan 450003,China)

机构地区：[1]阜外华中心血管病医院/河南省人民医院心脏中心药学部,河南郑州450003 [2]河南省人民医院药学部,河南郑州450003 [3]阜外华中心血管病医院/河南省人民医院心脏中心内分泌科,河南郑州450003 [4]阜外华中心血管病医院/河南省人民医院心脏中心肾内科,河南郑州450003

出　　处：《中国医学工程》2023年第2期1-5,共5页China Medical Engineering

基　　金：2019年河南省医学科技攻关计划(联合共建)项目(LHGJ20190812)。

摘　　要：目的 探讨舒洛地特对糖尿病肾病患者多种尿蛋白的改善效果及安全性。方法 采用随机数字表法将112例糖尿病肾病患者分为观察组和对照组,各56例,两组患者均给予基础治疗并严格控制饮食,对照组给予前列地尔治疗,观察组在对照组基础上联合舒洛地特治疗,两组均连续治疗4个月。比较两组患者治疗前、治疗2个月、4个月尿蛋白、肾功能变化及治疗期间不良反应发生情况。结果 与治疗前比较,治疗2个月、4个月两组患者24 h尿蛋白定量(24 h Alb)、尿β2-微球蛋白(β2-MG)、α1-微球蛋白(α1-MG)及尿单核细胞趋化蛋白1 (UMCP-1)水平均逐渐降低,且治疗后同一时间观察组上述指标水平均明显低于对照组(P<0.05)。与治疗前比较,治疗2个月、4个月两组患者尿白蛋白排泄率(UAER)、血肌酐(Scr)及尿素氮(BUN)水平均逐渐降低,且治疗后同一时间观察组上述指标水平均明显低于对照组(P<0.05)。两组并发症发生率比较,差异无统计学意义(12.50%vs. 10.71%)(P>0.05)。结论 在常规治疗基础上联合舒洛地特可更明显地降低糖尿病肾病患者多种尿蛋白水平,改善患者肾功能,安全有效,值得临床推广使用。【Objective】To investigate the improvement effect and safety of sulodexide on various urine proteins in patients with diabetic nephropathy. 【Methods】A total of 112 diabetic nephropathy patients were divide into observation group and control group according to the random number table method, 56 cases in each group, both groups were given basic treatment and strict diet control, the control group was given alprostadil treatment, the observation group combined with sulodexide on the base of the control group, both groups were treated continuously for 4 months. The urinary protein, renal function changes before treatment, 2 months and 4 months after treatment and occurrence of adverse reactions during treatment between the two groups were compared.【Results】Compared with before treatment, the levels of 24 hour urine protein quantification(24 h Alb), urine β2-microglobulin(urine β2-MG), α1-microglobulin(α1-MG) and urinary monocyte chemoattractant protein 1(UMCP-1) of the two groups gradually decreased after 2 and 4 months of treatment, and at the same time after treatment, the above indicators in the observation group were significantly lower than the control group(all P<0.05). Compared with before treatment, the levels of urinary albumin excretion rate(UAER), serum creatinine(Scr) and urea nitrogen(BUN) of the two groups gradually decreased after 2 and 4 months of treatment,and at the same time after treatment, the above indicators in the observation group were significantly lower than the control group(all P<0.05). There was no significant difference in the incidence of complications between the two groups(12.50% vs. 10.71%)(P>0.05). 【Conclusion】Combined with sulodexide on the basis of conventional treatment can significantly reduce the level of various urinary proteins in patients with diabetic nephropathy, improve the renal function of patients, safe and effective, and it is worthy of clinical promotion.

关 键 词：糖尿病肾病 舒洛地特 尿蛋白 安全性 

分 类 号：R587[医药卫生—内分泌]